Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

15,396 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Discovery of a pyrazolo[1,5-a]pyrimidine derivative (MT-3014) as a highly selective PDE10A inhibitor via core structure transformation from the stilbene moiety.
Koizumi Y, Tanaka Y, Matsumura T, Kadoh Y, Miyoshi H, Hongu M, Takedomi K, Kotera J, Sasaki T, Taniguchi H, Watanabe Y, Takakuwa M, Kojima K, Baba N, Nakamura I, Kawanishi E. Koizumi Y, et al. Among authors: tanaka y. Bioorg Med Chem. 2019 Aug 1;27(15):3440-3450. doi: 10.1016/j.bmc.2019.06.021. Epub 2019 Jun 19. Bioorg Med Chem. 2019. PMID: 31235264
Discovery and preclinical profile of teneligliptin (3-[(2S,4S)-4-[4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl]pyrrolidin-2-ylcarbonyl]thiazolidine): a highly potent, selective, long-lasting and orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
Yoshida T, Akahoshi F, Sakashita H, Kitajima H, Nakamura M, Sonda S, Takeuchi M, Tanaka Y, Ueda N, Sekiguchi S, Ishige T, Shima K, Nabeno M, Abe Y, Anabuki J, Soejima A, Yoshida K, Takashina Y, Ishii S, Kiuchi S, Fukuda S, Tsutsumiuchi R, Kosaka K, Murozono T, Nakamaru Y, Utsumi H, Masutomi N, Kishida H, Miyaguchi I, Hayashi Y. Yoshida T, et al. Among authors: tanaka y. Bioorg Med Chem. 2012 Oct 1;20(19):5705-19. doi: 10.1016/j.bmc.2012.08.012. Epub 2012 Aug 17. Bioorg Med Chem. 2012. PMID: 22959556
Discovery of 2-[(E)-2-(7-Fluoro-3-methylquinoxalin-2-yl)vinyl]-6-pyrrolidin-1-yl-N-(tetrahydro-2H-pyran-4-yl)pyrimidin-4-amine Hydrochloride as a Highly Selective PDE10A Inhibitor.
Kadoh Y, Miyoshi H, Matsumura T, Tanaka Y, Hongu M, Kimura M, Takedomi K, Omori K, Kotera J, Sasaki T, Kobayashi T, Taniguchi H, Watanabe Y, Kojima K, Sakamoto T, Himiyama T, Kawanishi E. Kadoh Y, et al. Among authors: tanaka y. Chem Pharm Bull (Tokyo). 2018;66(3):243-250. doi: 10.1248/cpb.c17-00783. Chem Pharm Bull (Tokyo). 2018. PMID: 29491258 Free article.
Efficacy of anifrolumab on systemic lupus erythematosus patients with serological manifestations: A post hoc analysis of the Japan subgroup of the TULIP-2 Trial.
Tanaka Y, Atsumi T, Okada M, Miyamura T, Ishii T, Nishiyama S, Matsumura R, Hayashi N, Matsumoto T, Yabe-Wada T, Yamaguchi Y, Abreu G, Lindholm C, Takeuchi T. Tanaka Y, et al. Mod Rheumatol. 2025 Jan 17:roae111. doi: 10.1093/mr/roae111. Online ahead of print. Mod Rheumatol. 2025. PMID: 39821415
A phase I/II study of adoptive immunotherapy using donor liver graft-derived NK cell-enriched immune cells to prevent severe infection after liver transplantation.
Ohira M, Imaoka Y, Sato K, Imaoka K, Bekki T, Yano T, Nakano R, Sakai H, Kuroda S, Tahara H, Ide K, Kobayashi T, Tanaka Y, Tanaka J, Ohdan H. Ohira M, et al. Among authors: tanaka y. PLoS One. 2025 Jan 16;20(1):e0313102. doi: 10.1371/journal.pone.0313102. eCollection 2025. PLoS One. 2025. PMID: 39820189 Clinical Trial.
15,396 results
You have reached the last available page of results. Please see the User Guide for more information.